檢索結果 - Gregory M. Lubiniecki

Refine Results
  1. 1
    Development of a Companion Diagnostic for Pembrolizumab in Non–Small Cell Lung Cancer Using Immunohistochemistry for Programmed Death Ligand-1

    Development of a Companion Diagnostic for Pembrolizumab in Non–Small Cell Lung Cancer Using Immunohistochemistry for Programmed Death Ligand-1 由 Marisa Dolled‐Filhart, Charlotte Roach, Grant Toland, Dave Stanforth, Malinka Jansson, Gregory M. Lubiniecki, Gary Ponto, Kenneth Emancipator

    出版 2016
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  2. 2
    The LEAP Program: Lenvatinib Plus Pembrolizumab for the Treatment of Advanced Solid Tumors

    The LEAP Program: Lenvatinib Plus Pembrolizumab for the Treatment of Advanced Solid Tumors 由 Matthew H. Taylor, Emmett V. Schmidt, Corina E. Dutcus, Elaine M. Pinheiro, Yasuhiro Funahashi, Gregory M. Lubiniecki, Drew Rasco

    出版 2020
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  3. 3
    Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic

    Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic 由 S. Peter Kang, Kevin Gergich, Gregory M. Lubiniecki, Dinesh P. de Alwis, C. Chen, M A B Tice, Eric H. Rubin

    出版 2017
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  4. 4
    Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With First-line Therapies for Medicare Patients 65 Years and Older With Advanced Non–small-cell Lung Cancer: A Retrospective Study

    Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With First-line Therapies for Medicare Patients 65 Years and Older With Advan... 由 Marisa A. Bittoni, Ashwini Arunachalam, Haojie Li, Ramon E. Camacho, Jinghua He, Yichen Zhong, Gregory M. Lubiniecki, David P. Carbone

    出版 2018
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  5. 5
    A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome

    A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome 由 Mark Kirschbaum, Ivana Gojo, Stuart L. Goldberg, Christopher Bredeson, Lisa Kujawski, Allen S. Yang, Peter Marks, Paul Frankel, Xing Sun, Alessandra Tosolini, Joseph Eid, Gregory M. Lubiniecki, Jean–Pierre J. Issa

    出版 2014
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  6. 6
    Lenvatinib dose, efficacy, and safety in the treatment of multiple malignancies

    Lenvatinib dose, efficacy, and safety in the treatment of multiple malignancies 由 Robert J. Motzer, Matthew H. Taylor, T.R. Jeffry Evans, Takuji Okusaka, Hilary Glen, Gregory M. Lubiniecki, Corina E. Dutcus, Alan D. Smith, Chinyere E. Okpara, Ziad Hussein, Seiichi Hayato, Toshiyuki Tamai, Vicky Makker

    出版 2022
    獲取全文
    Revisão
    加到收藏夾
    Saved in:
  7. 7
    PS1 Phase 3 KEYNOTE-042 Study: Pembrolizumab vs Platinum-Based Chemotherapy as 1l Therapy for Advanced NSCLC with a PD-L1 TPS ≥1%

    PS1 Phase 3 KEYNOTE-042 Study: Pembrolizumab vs Platinum-Based Chemotherapy as 1l Therapy for Advanced NSCLC with a PD-L1 TPS ≥1% 由 Gilberto Lopes, Yi‐Long Wu, Iveta Kudaba, Dariusz M. Kowalski, B. Cho, Hande Turna, Gilberto de Castro, Vichien Srimuninnimit, К. К. Лактионов, Igor Bondarenko, Kazuo Kubota, Gregory M. Lubiniecki, J. Zhang, Debra Kush, Tony Mok

    出版 2018
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  8. 8
    Assessment of health-related quality of life (HRQoL) in KEYNOTE-010: A phase 2/3 study of pembrolizumab vs docetaxel in patients with previously treated advanced NSCLC

    Assessment of health-related quality of life (HRQoL) in KEYNOTE-010: A phase 2/3 study of pembrolizumab vs docetaxel in patients with previously treated advanced NSCLC 由 Fabrice Barlési, Edward B. Garon, Dong‐Wook Kim, Enriqueta Felip, J. Y. Han, Jin‐Hoi Kim, M-J. Ahn, Mary J. Fidler, Matthew A. Gubens, G. Castro, Veerle Surmont, Q. Li, Anne C. Deitz, Gregory M. Lubiniecki, Roy S. Herbst

    出版 2016
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  9. 9
    Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

    Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer 由 Martin Reck, Delvys Rodríguez‐Abreu, Andrew Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinéad Cuffe, Mary O’Brien, Suman Rao, Katsuyuki Hotta, Melanie A. Leiby, Gregory M. Lubiniecki, Yue Shentu, Reshma Rangwala, Julie R. Brahmer

    出版 2016
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  10. 10
    Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1–Expressing NSCLC

    Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1–Expres... 由 Fabrice Barlési, Edward B. Garon, Dong‐Wan Kim, Enriqueta Felip, Ji‐Youn Han, Joo-Hang Kim, Myung‐Ju Ahn, Mary J. Fidler, Matthew A. Gubens, Gilberto de Castro, Veerle Surmont, Qiao Li, Anne C. Deitz, Gregory M. Lubiniecki, Roy S. Herbst

    出版 2019
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  11. 11
    Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial

    Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial 由 Rina Hui, Edward B. Garon, J.W. Goldman, Natasha B. Leighl, Matthew D. Hellmann, Amita Patnaik, Leena Gandhi, Joseph P. Eder, Myung‐Ju Ahn, Leora Horn, Enriqueta Felip, Enric Carcereny, Reshma Rangwala, Gregory M. Lubiniecki, J. Zhang, Kenneth Emancipator, Charlotte Roach, Naiyer A. Rizvi

    出版 2017
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  12. 12
    LBA3_PR KEYNOTE-010: Phase 2/3 study of pembrolizumab (MK-3475) vs docetaxel for PD-L1–positive NSCLC after platinum-based therapy

    LBA3_PR KEYNOTE-010: Phase 2/3 study of pembrolizumab (MK-3475) vs docetaxel for PD-L1–positive NSCLC after platinum-based therapy 由 Roy S. Herbst, D.-W. Kim, Enriqueta Felip, Jose Luis Pérez‐Gracia, E.B. Garon, Ji‐Youn Han, Julian R. Molina, J.-H. Kim, R. Gervais, Myung‐Ju Ahn, Margarita Majem, Mary J. Fidler, Gilberto de Castro, Marcelo Garrido, Gregory M. Lubiniecki, Yue Shentu, E. Im, Paul Baas

    出版 2015
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  13. 13
    Pembrolizumab (pembro) vs docetaxel (doce) for previously treated, PD-L1–expressing NSCLC: Updated outcomes of KEYNOTE-010

    Pembrolizumab (pembro) vs docetaxel (doce) for previously treated, PD-L1–expressing NSCLC: Updated outcomes of KEYNOTE-010 由 Roy S. Herbst, Paul Baas, Dong‐Wook Kim, Enriqueta Felip, Jose Luis Pérez‐Gracia, J. Y. Han, Juan Pablo Molina, Jae‐Hun Kim, Catherine Dubos Arvis, M-J. Ahn, Margarita Majem, Mary J. Fidler, Gilberto de Castro, Marcelo Garrido, Yue Shentu, Gregory M. Lubiniecki, E.B. Garon

    出版 2016
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  14. 14
    Association between tissue TMB (tTMB) and clinical outcomes with pembrolizumab monotherapy (pembro) in PD-L1-positive advanced NSCLC in the KEYNOTE-010 and -042 trials

    Association between tissue TMB (tTMB) and clinical outcomes with pembrolizumab monotherapy (pembro) in PD-L1-positive advanced NSCLC in the KEYNOTE-010 and -042 trials 由 Roy S. Herbst, G. Lopes, D.M. Kowalski, Mizuho Nishio, Yechen Wu, Gilberto de Castro, Paul Baas, D.-W. Kim, Matthew A. Gubens, Rǎzvan Cristescu, Deepti Aurora-Garg, Andrew Albright, Mark Ayers, Andrey Loboda, Jared Lunceford, Julie Kobie, Gregory M. Lubiniecki, Maria C. Pietanza, Bilal Piperdi, Tony Mok

    出版 2019
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  15. 15
    Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) for metastatic NSCLC: Tissue TMB (tTMB) and outcomes in KEYNOTE-021, 189, and 407

    Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) for metastatic NSCLC: Tissue TMB (tTMB) and outcomes in KEYNOTE-021, 189, and 407 由 Luis Paz‐Ares, Corey J. Langer, Silvia Novello, Balázs Halmos, Ying Cheng, Shirish M. Gadgeel, Rina Hui, Shunichi Sugawara, Hossein Borghaei, Rǎzvan Cristescu, Deepti Aurora-Garg, Andrew Albright, Andrey Loboda, Julie Kobie, Jared Lunceford, Mark Ayers, Gregory M. Lubiniecki, M. Catherine Pietanza, Bilal Piperdi, Marina Chiara Garassino

    出版 2019
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  16. 16
    OA04.06 Evaluation of TMB in KEYNOTE-189: Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy for Nonsquamous NSCLC

    OA04.06 Evaluation of TMB in KEYNOTE-189: Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy for Nonsquamous NSCLC 由 Marina Chiara Garassino, Delvys Rodríguez‐Abreu, Shirish M. Gadgeel, Emilio Esteban, Enriqueta Felip, G. Speranza, Martin Reck, Rina Hui, Michael Boyer, Rǎzvan Cristescu, Deepti Aurora-Garg, Andrew Albright, Andrey Loboda, Julie Kobie, Jared Lunceford, Mark Ayers, Gregory M. Lubiniecki, Bilal Piperdi, M. Catherine Pietanza, Edward B. Garon

    出版 2019
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  17. 17
    Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study

    Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study 由 Roy S. Herbst, Edward B. Garon, Dong‐Wan Kim, Byoung Chul Cho, Jose Luis Pérez‐Gracia, Ji‐Youn Han, Catherine Dubos Arvis, Margarita Majem, Martin Förster, I. Monnet, Silvia Novello, Zsuzsanna Szalai, Matthew A. Gubens, Wu‐Chou Su, Giovanni Luca Ceresoli, Ayman Samkari, Erin Jensen, Gregory M. Lubiniecki, Paul Baas

    出版 2020
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  18. 18
    Antitumor Activity of Pembrolizumab (Pembro; Mk-3475) and Correlation with Programmed Death Ligand 1 (Pd-L1) Expression in a Pooled Analysis of Patients (Pts) with Advanced Non–Small Cell Lung Carcinoma (Nsclc)

    Antitumor Activity of Pembrolizumab (Pembro; Mk-3475) and Correlation with Programmed Death Ligand 1 (Pd-L1) Expression in a Pooled Analysis of Patients (Pts) with Advanced Non–Sma... 由 Edward B. Garon, Leena Gandhi, Naiyer A. Rizvi, Rina Hui, Ani Sarkis Balmanoukian, Amita Patnaik, Joseph P. Eder, George Blumenshein, Charu Aggarwal, J.C. Soria, Myung‐Ju Ahn, Matthew A. Gubens, Suresh S. Ramalingam, Elizabeth A. Johnson, Hendrik‐Tobias Arkenau, Gregory M. Lubiniecki, J. Zhang, R. Rutledge, Kenneth Emancipator, Natasha B. Leighl

    出版 2014
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  19. 19
    Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

    Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer 由 Luis Paz‐Ares, Alexander Luft, David Vicente, Ali Tafreshi, Mahmut Gümüş, Julien Mazières, Bárbara Hermes, Filiz Çay Şenler, Tibor Csőszi, Andrea Fülöp, Jerónimo Rafael Rodríguez‐Cid, Jonathan Wilson, Shunichi Sugawara, Terufumi Kato, Ki Hyeong Lee, Ying Cheng, Silvia Novello, Balázs Halmos, Xiaodong Li, Gregory M. Lubiniecki, Bilal Piperdi, Dariusz M. Kowalski, Keynote Investigators

    出版 2018
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  20. 20
    Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer

    Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer 由 Manash Chatterjee, David C. Turner, Enriqueta Felip, H. Léna, Federico Cappuzzo, Leora Horn, Edward B. Garon, Rina Hui, Hendrik‐Tobias Arkenau, Matthew A. Gubens, Matthew D. Hellmann, Dezuo Dong, C. Li, Kapil Mayawala, Tomoko Freshwater, Malidi Ahamadi, Julie A. Stone, Gregory M. Lubiniecki, J. Zhang, E. Im, Dinesh P. de Alwis, Anna Kondic, Øystein Fløtten

    出版 2016
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:

檢索工具: